nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Pazopanib—kidney cancer	0.282	0.436	CbGbCtD
Dolutegravir—UGT1A1—Erlotinib—kidney cancer	0.202	0.311	CbGbCtD
Dolutegravir—UGT1A1—Sorafenib—kidney cancer	0.164	0.253	CbGbCtD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—FOSL2—kidney cancer	0.0152	0.164	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CDH6—kidney cancer	0.00719	0.0779	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—CARD11—kidney cancer	0.00573	0.062	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—NF2—kidney cancer	0.00545	0.059	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—kidney cancer	0.00437	0.0473	CbGpPWpGaD
Dolutegravir—UGT1A1—Porphyrin metabolism—ALAD—kidney cancer	0.00375	0.0406	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.00299	0.0324	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—PAX6—kidney cancer	0.00259	0.0281	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.00252	0.0273	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL13—kidney cancer	0.00251	0.0272	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—kidney cancer	0.00248	0.0268	CbGpPWpGaD
Dolutegravir—UGT1A1—urine—kidney cancer	0.0024	0.675	CbGeAlD
Dolutegravir—UGT1A1—Irinotecan Pathway—BCHE—kidney cancer	0.00214	0.0232	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—EGR1—kidney cancer	0.00191	0.0206	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—RAF1—kidney cancer	0.0018	0.0195	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—RELA—kidney cancer	0.00179	0.0194	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—JUN—kidney cancer	0.00157	0.017	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—kidney cancer	0.00152	0.0165	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HIF1A—kidney cancer	0.00133	0.0144	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK3—kidney cancer	0.0013	0.0141	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—kidney cancer	0.00128	0.0139	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK1—kidney cancer	0.00124	0.0134	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1A1—kidney cancer	0.00121	0.0131	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—APC—kidney cancer	0.00116	0.0126	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	0.00115	0.0124	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—kidney cancer	0.00107	0.0116	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—ACY1—kidney cancer	0.00102	0.0111	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CTNNB1—kidney cancer	0.000875	0.00948	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000831	0.009	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—JUN—kidney cancer	0.000799	0.00866	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	0.000793	0.00859	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	0.000782	0.00847	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—kidney cancer	0.000709	0.00768	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—kidney cancer	0.000698	0.00757	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC5A3—kidney cancer	0.000614	0.00665	CbGpPWpGaD
Dolutegravir—UGT1A1—renal system—kidney cancer	0.000587	0.165	CbGeAlD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000572	0.0062	CbGpPWpGaD
Dolutegravir—UGT1A1—kidney—kidney cancer	0.000568	0.16	CbGeAlD
Dolutegravir—UGT1A1—Phase II conjugation—GSTT1—kidney cancer	0.000564	0.00611	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—ALDH1A1—kidney cancer	0.000562	0.00608	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—KEAP1—kidney cancer	0.000536	0.00581	CbGpPWpGaD
Dolutegravir—Abdominal pain upper—Paclitaxel—kidney cancer	0.000521	0.00203	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000517	0.00202	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Pazopanib—kidney cancer	0.000517	0.00202	CcSEcCtD
Dolutegravir—Renal failure—Gemcitabine—kidney cancer	0.000516	0.00201	CcSEcCtD
Dolutegravir—Mental disorder—Sunitinib—kidney cancer	0.000514	0.00201	CcSEcCtD
Dolutegravir—Flatulence—Sunitinib—kidney cancer	0.000504	0.00196	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Paclitaxel—kidney cancer	0.000503	0.00196	CcSEcCtD
Dolutegravir—Abdominal pain—Pazopanib—kidney cancer	0.0005	0.00195	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000499	0.00195	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Gemcitabine—kidney cancer	0.000496	0.00194	CcSEcCtD
Dolutegravir—Hypersensitivity—Temsirolimus—kidney cancer	0.000495	0.00193	CcSEcCtD
Dolutegravir—Renal impairment—Capecitabine—kidney cancer	0.000492	0.00192	CcSEcCtD
Dolutegravir—Urinary tract disorder—Vincristine—kidney cancer	0.00049	0.00191	CcSEcCtD
Dolutegravir—Nervous system disorder—Everolimus—kidney cancer	0.00049	0.00191	CcSEcCtD
Dolutegravir—Urethral disorder—Vincristine—kidney cancer	0.000487	0.0019	CcSEcCtD
Dolutegravir—Skin disorder—Everolimus—kidney cancer	0.000485	0.00189	CcSEcCtD
Dolutegravir—Asthenia—Temsirolimus—kidney cancer	0.000482	0.00188	CcSEcCtD
Dolutegravir—Pruritus—Temsirolimus—kidney cancer	0.000475	0.00185	CcSEcCtD
Dolutegravir—Nervous system disorder—Erlotinib—kidney cancer	0.000472	0.00184	CcSEcCtD
Dolutegravir—Skin disorder—Erlotinib—kidney cancer	0.000468	0.00183	CcSEcCtD
Dolutegravir—Urinary tract disorder—Gemcitabine—kidney cancer	0.000465	0.00181	CcSEcCtD
Dolutegravir—Urethral disorder—Gemcitabine—kidney cancer	0.000462	0.0018	CcSEcCtD
Dolutegravir—Neutropenia—Paclitaxel—kidney cancer	0.000461	0.0018	CcSEcCtD
Dolutegravir—Diarrhoea—Temsirolimus—kidney cancer	0.000459	0.00179	CcSEcCtD
Dolutegravir—Asthenia—Pazopanib—kidney cancer	0.000454	0.00177	CcSEcCtD
Dolutegravir—Insomnia—Everolimus—kidney cancer	0.000452	0.00176	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000449	0.00175	CcSEcCtD
Dolutegravir—Pruritus—Pazopanib—kidney cancer	0.000447	0.00175	CcSEcCtD
Dolutegravir—Hyperglycaemia—Paclitaxel—kidney cancer	0.000444	0.00173	CcSEcCtD
Dolutegravir—Dizziness—Temsirolimus—kidney cancer	0.000444	0.00173	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Doxorubicin—kidney cancer	0.000439	0.00171	CcSEcCtD
Dolutegravir—Blood creatinine increased—Capecitabine—kidney cancer	0.000438	0.00171	CcSEcCtD
Dolutegravir—Insomnia—Erlotinib—kidney cancer	0.000436	0.0017	CcSEcCtD
Dolutegravir—Mental disorder—Vincristine—kidney cancer	0.000435	0.0017	CcSEcCtD
Dolutegravir—Diarrhoea—Pazopanib—kidney cancer	0.000433	0.00169	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000432	0.00169	CcSEcCtD
Dolutegravir—Renal failure—Paclitaxel—kidney cancer	0.000432	0.00168	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Everolimus—kidney cancer	0.000431	0.00168	CcSEcCtD
Dolutegravir—Fatigue—Everolimus—kidney cancer	0.00043	0.00168	CcSEcCtD
Dolutegravir—Inflammation—Doxorubicin—kidney cancer	0.000428	0.00167	CcSEcCtD
Dolutegravir—Abdominal pain upper—Capecitabine—kidney cancer	0.000427	0.00167	CcSEcCtD
Dolutegravir—Vomiting—Temsirolimus—kidney cancer	0.000427	0.00166	CcSEcCtD
Dolutegravir—Immune system disorder—Gemcitabine—kidney cancer	0.000425	0.00166	CcSEcCtD
Dolutegravir—Nervous system disorder—Sorafenib—kidney cancer	0.000425	0.00166	CcSEcCtD
Dolutegravir—Rash—Temsirolimus—kidney cancer	0.000423	0.00165	CcSEcCtD
Dolutegravir—Dermatitis—Temsirolimus—kidney cancer	0.000423	0.00165	CcSEcCtD
Dolutegravir—Skin disorder—Sorafenib—kidney cancer	0.000421	0.00164	CcSEcCtD
Dolutegravir—Headache—Temsirolimus—kidney cancer	0.00042	0.00164	CcSEcCtD
Dolutegravir—Dizziness—Pazopanib—kidney cancer	0.000418	0.00163	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000416	0.00162	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Paclitaxel—kidney cancer	0.000415	0.00162	CcSEcCtD
Dolutegravir—Fatigue—Erlotinib—kidney cancer	0.000415	0.00162	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Capecitabine—kidney cancer	0.000413	0.00161	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—kidney cancer	0.000411	0.0016	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Vinblastine—kidney cancer	0.00041	0.0016	CcSEcCtD
Dolutegravir—Nervous system disorder—Sunitinib—kidney cancer	0.000409	0.0016	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Everolimus—kidney cancer	0.000408	0.00159	CcSEcCtD
Dolutegravir—Skin disorder—Sunitinib—kidney cancer	0.000405	0.00158	CcSEcCtD
Dolutegravir—Vomiting—Pazopanib—kidney cancer	0.000402	0.00157	CcSEcCtD
Dolutegravir—Rash—Pazopanib—kidney cancer	0.000399	0.00156	CcSEcCtD
Dolutegravir—Nausea—Temsirolimus—kidney cancer	0.000399	0.00156	CcSEcCtD
Dolutegravir—Dermatitis—Pazopanib—kidney cancer	0.000398	0.00155	CcSEcCtD
Dolutegravir—Abdominal pain—Vinblastine—kidney cancer	0.000396	0.00155	CcSEcCtD
Dolutegravir—Headache—Pazopanib—kidney cancer	0.000396	0.00155	CcSEcCtD
Dolutegravir—Abdominal pain—Everolimus—kidney cancer	0.000395	0.00154	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Erlotinib—kidney cancer	0.000394	0.00154	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTP1—kidney cancer	0.000391	0.00423	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Paclitaxel—kidney cancer	0.000389	0.00152	CcSEcCtD
Dolutegravir—Vertigo—Vincristine—kidney cancer	0.000388	0.00151	CcSEcCtD
Dolutegravir—Abdominal discomfort—Capecitabine—kidney cancer	0.000388	0.00151	CcSEcCtD
Dolutegravir—Urethral disorder—Paclitaxel—kidney cancer	0.000387	0.00151	CcSEcCtD
Dolutegravir—Abdominal pain—Erlotinib—kidney cancer	0.000381	0.00149	CcSEcCtD
Dolutegravir—Neutropenia—Capecitabine—kidney cancer	0.000378	0.00147	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—kidney cancer	0.000378	0.00147	CcSEcCtD
Dolutegravir—Insomnia—Sunitinib—kidney cancer	0.000377	0.00147	CcSEcCtD
Dolutegravir—Nausea—Pazopanib—kidney cancer	0.000376	0.00147	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000374	0.00146	CcSEcCtD
Dolutegravir—Fatigue—Sorafenib—kidney cancer	0.000374	0.00146	CcSEcCtD
Dolutegravir—Hypersensitivity—Vinblastine—kidney cancer	0.000369	0.00144	CcSEcCtD
Dolutegravir—Hypersensitivity—Everolimus—kidney cancer	0.000368	0.00143	CcSEcCtD
Dolutegravir—Hyperglycaemia—Capecitabine—kidney cancer	0.000365	0.00142	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00036	0.0014	CcSEcCtD
Dolutegravir—Asthenia—Vinblastine—kidney cancer	0.00036	0.0014	CcSEcCtD
Dolutegravir—Fatigue—Sunitinib—kidney cancer	0.00036	0.0014	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—kidney cancer	0.000359	0.00389	CbGpPWpGaD
Dolutegravir—Asthenia—Everolimus—kidney cancer	0.000358	0.0014	CcSEcCtD
Dolutegravir—Immune system disorder—Paclitaxel—kidney cancer	0.000356	0.00139	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Sorafenib—kidney cancer	0.000354	0.00138	CcSEcCtD
Dolutegravir—Renal failure—Capecitabine—kidney cancer	0.000354	0.00138	CcSEcCtD
Dolutegravir—Pruritus—Everolimus—kidney cancer	0.000353	0.00138	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000347	0.00135	CcSEcCtD
Dolutegravir—Nervous system disorder—Vincristine—kidney cancer	0.000346	0.00135	CcSEcCtD
Dolutegravir—Asthenia—Erlotinib—kidney cancer	0.000346	0.00135	CcSEcCtD
Dolutegravir—Mental disorder—Paclitaxel—kidney cancer	0.000345	0.00135	CcSEcCtD
Dolutegravir—Diarrhoea—Vinblastine—kidney cancer	0.000343	0.00134	CcSEcCtD
Dolutegravir—Abdominal pain—Sorafenib—kidney cancer	0.000343	0.00134	CcSEcCtD
Dolutegravir—Diarrhoea—Everolimus—kidney cancer	0.000342	0.00133	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Sunitinib—kidney cancer	0.000341	0.00133	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Capecitabine—kidney cancer	0.000341	0.00133	CcSEcCtD
Dolutegravir—Pruritus—Erlotinib—kidney cancer	0.000341	0.00133	CcSEcCtD
Dolutegravir—Fatigue—Dactinomycin—kidney cancer	0.00034	0.00133	CcSEcCtD
Dolutegravir—Flatulence—Paclitaxel—kidney cancer	0.000338	0.00132	CcSEcCtD
Dolutegravir—Dizziness—Vinblastine—kidney cancer	0.000331	0.00129	CcSEcCtD
Dolutegravir—Dizziness—Everolimus—kidney cancer	0.00033	0.00129	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTT1—kidney cancer	0.00033	0.00357	CbGpPWpGaD
Dolutegravir—Abdominal pain—Sunitinib—kidney cancer	0.00033	0.00129	CcSEcCtD
Dolutegravir—Diarrhoea—Erlotinib—kidney cancer	0.00033	0.00129	CcSEcCtD
Dolutegravir—Nervous system disorder—Gemcitabine—kidney cancer	0.000328	0.00128	CcSEcCtD
Dolutegravir—Skin disorder—Gemcitabine—kidney cancer	0.000325	0.00127	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SLC5A5—kidney cancer	0.000324	0.00351	CbGpPWpGaD
Dolutegravir—Hepatitis—Capecitabine—kidney cancer	0.000324	0.00126	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000323	0.00126	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	0.000322	0.00349	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Capecitabine—kidney cancer	0.00032	0.00125	CcSEcCtD
Dolutegravir—Hypersensitivity—Sorafenib—kidney cancer	0.000319	0.00125	CcSEcCtD
Dolutegravir—Insomnia—Vincristine—kidney cancer	0.000319	0.00124	CcSEcCtD
Dolutegravir—Vomiting—Vinblastine—kidney cancer	0.000319	0.00124	CcSEcCtD
Dolutegravir—Dizziness—Erlotinib—kidney cancer	0.000319	0.00124	CcSEcCtD
Dolutegravir—Vomiting—Everolimus—kidney cancer	0.000317	0.00124	CcSEcCtD
Dolutegravir—Urethral disorder—Capecitabine—kidney cancer	0.000317	0.00124	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—kidney cancer	0.000317	0.00124	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	0.000315	0.00342	CbGpPWpGaD
Dolutegravir—Rash—Everolimus—kidney cancer	0.000315	0.00123	CcSEcCtD
Dolutegravir—Dermatitis—Everolimus—kidney cancer	0.000315	0.00123	CcSEcCtD
Dolutegravir—Headache—Vinblastine—kidney cancer	0.000314	0.00122	CcSEcCtD
Dolutegravir—Headache—Everolimus—kidney cancer	0.000313	0.00122	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SLC2A1—kidney cancer	0.000313	0.00339	CbGpPWpGaD
Dolutegravir—Abdominal pain—Dactinomycin—kidney cancer	0.000312	0.00122	CcSEcCtD
Dolutegravir—Asthenia—Sorafenib—kidney cancer	0.000311	0.00121	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—PTGS1—kidney cancer	0.000309	0.00335	CbGpPWpGaD
Dolutegravir—Vertigo—Paclitaxel—kidney cancer	0.000308	0.0012	CcSEcCtD
Dolutegravir—Hypersensitivity—Sunitinib—kidney cancer	0.000307	0.0012	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	0.000307	0.00332	CbGpPWpGaD
Dolutegravir—Pruritus—Sorafenib—kidney cancer	0.000307	0.0012	CcSEcCtD
Dolutegravir—Vomiting—Erlotinib—kidney cancer	0.000306	0.00119	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Vincristine—kidney cancer	0.000305	0.00119	CcSEcCtD
Dolutegravir—Fatigue—Vincristine—kidney cancer	0.000304	0.00119	CcSEcCtD
Dolutegravir—Rash—Erlotinib—kidney cancer	0.000304	0.00118	CcSEcCtD
Dolutegravir—Dermatitis—Erlotinib—kidney cancer	0.000303	0.00118	CcSEcCtD
Dolutegravir—Insomnia—Gemcitabine—kidney cancer	0.000303	0.00118	CcSEcCtD
Dolutegravir—Headache—Erlotinib—kidney cancer	0.000302	0.00118	CcSEcCtD
Dolutegravir—Asthenia—Sunitinib—kidney cancer	0.000299	0.00117	CcSEcCtD
Dolutegravir—Nausea—Vinblastine—kidney cancer	0.000298	0.00116	CcSEcCtD
Dolutegravir—Nausea—Everolimus—kidney cancer	0.000297	0.00116	CcSEcCtD
Dolutegravir—Diarrhoea—Sorafenib—kidney cancer	0.000297	0.00116	CcSEcCtD
Dolutegravir—Pruritus—Sunitinib—kidney cancer	0.000295	0.00115	CcSEcCtD
Dolutegravir—Immune system disorder—Capecitabine—kidney cancer	0.000292	0.00114	CcSEcCtD
Dolutegravir—Hypersensitivity—Dactinomycin—kidney cancer	0.000291	0.00113	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—EGR1—kidney cancer	0.00029	0.00314	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00029	0.00113	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000289	0.00113	CcSEcCtD
Dolutegravir—Fatigue—Gemcitabine—kidney cancer	0.000288	0.00113	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Vincristine—kidney cancer	0.000288	0.00113	CcSEcCtD
Dolutegravir—Dizziness—Sorafenib—kidney cancer	0.000287	0.00112	CcSEcCtD
Dolutegravir—Nausea—Erlotinib—kidney cancer	0.000286	0.00112	CcSEcCtD
Dolutegravir—Diarrhoea—Sunitinib—kidney cancer	0.000285	0.00111	CcSEcCtD
Dolutegravir—Mental disorder—Capecitabine—kidney cancer	0.000284	0.00111	CcSEcCtD
Dolutegravir—Asthenia—Dactinomycin—kidney cancer	0.000283	0.0011	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—kidney cancer	0.000282	0.0011	CcSEcCtD
Dolutegravir—Abdominal pain—Vincristine—kidney cancer	0.000279	0.00109	CcSEcCtD
Dolutegravir—Flatulence—Capecitabine—kidney cancer	0.000278	0.00108	CcSEcCtD
Dolutegravir—Dizziness—Sunitinib—kidney cancer	0.000276	0.00108	CcSEcCtD
Dolutegravir—Vomiting—Sorafenib—kidney cancer	0.000276	0.00107	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—kidney cancer	0.000275	0.00107	CcSEcCtD
Dolutegravir—Nervous system disorder—Paclitaxel—kidney cancer	0.000275	0.00107	CcSEcCtD
Dolutegravir—Rash—Sorafenib—kidney cancer	0.000273	0.00107	CcSEcCtD
Dolutegravir—Dermatitis—Sorafenib—kidney cancer	0.000273	0.00106	CcSEcCtD
Dolutegravir—Skin disorder—Paclitaxel—kidney cancer	0.000272	0.00106	CcSEcCtD
Dolutegravir—Headache—Sorafenib—kidney cancer	0.000272	0.00106	CcSEcCtD
Dolutegravir—Diarrhoea—Dactinomycin—kidney cancer	0.00027	0.00105	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000266	0.00104	CcSEcCtD
Dolutegravir—Vomiting—Sunitinib—kidney cancer	0.000265	0.00103	CcSEcCtD
Dolutegravir—Rash—Sunitinib—kidney cancer	0.000263	0.00103	CcSEcCtD
Dolutegravir—Dermatitis—Sunitinib—kidney cancer	0.000263	0.00102	CcSEcCtD
Dolutegravir—Headache—Sunitinib—kidney cancer	0.000261	0.00102	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTP1—kidney cancer	0.000261	0.00282	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Vincristine—kidney cancer	0.00026	0.00101	CcSEcCtD
Dolutegravir—Nausea—Sorafenib—kidney cancer	0.000257	0.001	CcSEcCtD
Dolutegravir—Insomnia—Paclitaxel—kidney cancer	0.000253	0.000988	CcSEcCtD
Dolutegravir—Vertigo—Capecitabine—kidney cancer	0.000253	0.000987	CcSEcCtD
Dolutegravir—Asthenia—Vincristine—kidney cancer	0.000253	0.000987	CcSEcCtD
Dolutegravir—Vomiting—Dactinomycin—kidney cancer	0.000251	0.000979	CcSEcCtD
Dolutegravir—Rash—Dactinomycin—kidney cancer	0.000249	0.000971	CcSEcCtD
Dolutegravir—Nausea—Sunitinib—kidney cancer	0.000248	0.000966	CcSEcCtD
Dolutegravir—Neutropenia—Doxorubicin—kidney cancer	0.000244	0.000951	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000242	0.000943	CcSEcCtD
Dolutegravir—Fatigue—Paclitaxel—kidney cancer	0.000242	0.000942	CcSEcCtD
Dolutegravir—Diarrhoea—Vincristine—kidney cancer	0.000241	0.000941	CcSEcCtD
Dolutegravir—Asthenia—Gemcitabine—kidney cancer	0.00024	0.000937	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—kidney cancer	0.00024	0.0026	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000238	0.000929	CcSEcCtD
Dolutegravir—Pruritus—Gemcitabine—kidney cancer	0.000237	0.000923	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—kidney cancer	0.000235	0.000917	CcSEcCtD
Dolutegravir—Nausea—Dactinomycin—kidney cancer	0.000235	0.000915	CcSEcCtD
Dolutegravir—Dizziness—Vincristine—kidney cancer	0.000233	0.00091	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000229	0.000894	CcSEcCtD
Dolutegravir—Diarrhoea—Gemcitabine—kidney cancer	0.000229	0.000893	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTP1—kidney cancer	0.000229	0.00248	CbGpPWpGaD
Dolutegravir—Renal failure—Doxorubicin—kidney cancer	0.000228	0.000891	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTP1—kidney cancer	0.000226	0.00244	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Capecitabine—kidney cancer	0.000225	0.00088	CcSEcCtD
Dolutegravir—Vomiting—Vincristine—kidney cancer	0.000224	0.000875	CcSEcCtD
Dolutegravir—Skin disorder—Capecitabine—kidney cancer	0.000223	0.000871	CcSEcCtD
Dolutegravir—Rash—Vincristine—kidney cancer	0.000222	0.000868	CcSEcCtD
Dolutegravir—Dermatitis—Vincristine—kidney cancer	0.000222	0.000867	CcSEcCtD
Dolutegravir—Abdominal pain—Paclitaxel—kidney cancer	0.000221	0.000864	CcSEcCtD
Dolutegravir—Headache—Vincristine—kidney cancer	0.000221	0.000862	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—kidney cancer	0.00022	0.000857	CcSEcCtD
Dolutegravir—Vomiting—Gemcitabine—kidney cancer	0.000213	0.00083	CcSEcCtD
Dolutegravir—Rash—Gemcitabine—kidney cancer	0.000211	0.000823	CcSEcCtD
Dolutegravir—Dermatitis—Gemcitabine—kidney cancer	0.000211	0.000822	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—kidney cancer	0.00021	0.00228	CbGpPWpGaD
Dolutegravir—Headache—Gemcitabine—kidney cancer	0.00021	0.000818	CcSEcCtD
Dolutegravir—Nausea—Vincristine—kidney cancer	0.00021	0.000817	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—kidney cancer	0.000209	0.000814	CcSEcCtD
Dolutegravir—Insomnia—Capecitabine—kidney cancer	0.000208	0.000811	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—kidney cancer	0.000207	0.00225	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Paclitaxel—kidney cancer	0.000206	0.000805	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—kidney cancer	0.000206	0.000804	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—kidney cancer	0.000204	0.000798	CcSEcCtD
Dolutegravir—Asthenia—Paclitaxel—kidney cancer	0.000201	0.000784	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1A1—kidney cancer	0.000199	0.00216	CbGpPWpGaD
Dolutegravir—Nausea—Gemcitabine—kidney cancer	0.000199	0.000775	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000198	0.000774	CcSEcCtD
Dolutegravir—Fatigue—Capecitabine—kidney cancer	0.000198	0.000773	CcSEcCtD
Dolutegravir—Pruritus—Paclitaxel—kidney cancer	0.000198	0.000773	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1A1—kidney cancer	0.000197	0.00213	CbGpPWpGaD
Dolutegravir—Diarrhoea—Paclitaxel—kidney cancer	0.000192	0.000748	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—kidney cancer	0.000188	0.000735	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Capecitabine—kidney cancer	0.000188	0.000733	CcSEcCtD
Dolutegravir—Dizziness—Paclitaxel—kidney cancer	0.000185	0.000723	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—kidney cancer	0.000183	0.000713	CcSEcCtD
Dolutegravir—Abdominal pain—Capecitabine—kidney cancer	0.000182	0.000709	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—kidney cancer	0.000179	0.000698	CcSEcCtD
Dolutegravir—Vomiting—Paclitaxel—kidney cancer	0.000178	0.000695	CcSEcCtD
Dolutegravir—Rash—Paclitaxel—kidney cancer	0.000177	0.000689	CcSEcCtD
Dolutegravir—Dermatitis—Paclitaxel—kidney cancer	0.000176	0.000688	CcSEcCtD
Dolutegravir—Headache—Paclitaxel—kidney cancer	0.000176	0.000685	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ACY1—kidney cancer	0.000175	0.0019	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Capecitabine—kidney cancer	0.000169	0.000661	CcSEcCtD
Dolutegravir—Nausea—Paclitaxel—kidney cancer	0.000166	0.000649	CcSEcCtD
Dolutegravir—Asthenia—Capecitabine—kidney cancer	0.000165	0.000643	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—kidney cancer	0.000163	0.000636	CcSEcCtD
Dolutegravir—Pruritus—Capecitabine—kidney cancer	0.000163	0.000635	CcSEcCtD
Dolutegravir—Diarrhoea—Capecitabine—kidney cancer	0.000157	0.000614	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000154	0.000599	CcSEcCtD
Dolutegravir—Dizziness—Capecitabine—kidney cancer	0.000152	0.000593	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PDHB—kidney cancer	0.000149	0.00161	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—POMC—kidney cancer	0.000149	0.00161	CbGpPWpGaD
Dolutegravir—Vomiting—Capecitabine—kidney cancer	0.000146	0.00057	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—kidney cancer	0.000145	0.000567	CcSEcCtD
Dolutegravir—Rash—Capecitabine—kidney cancer	0.000145	0.000565	CcSEcCtD
Dolutegravir—Dermatitis—Capecitabine—kidney cancer	0.000145	0.000565	CcSEcCtD
Dolutegravir—Headache—Capecitabine—kidney cancer	0.000144	0.000562	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—kidney cancer	0.000144	0.000562	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CCBL1—kidney cancer	0.00014	0.00152	CbGpPWpGaD
Dolutegravir—Nausea—Capecitabine—kidney cancer	0.000137	0.000533	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—kidney cancer	0.000134	0.000523	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000128	0.000499	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—kidney cancer	0.000128	0.000498	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PPAT—kidney cancer	0.000121	0.00132	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GLIPR1—kidney cancer	0.000121	0.00132	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000121	0.000473	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—kidney cancer	0.000117	0.000457	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—APRT—kidney cancer	0.000113	0.00122	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—FH—kidney cancer	0.000113	0.00122	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Doxorubicin—kidney cancer	0.000109	0.000426	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—kidney cancer	0.000106	0.000415	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—GPC3—kidney cancer	0.000106	0.00115	CbGpPWpGaD
Dolutegravir—Pruritus—Doxorubicin—kidney cancer	0.000105	0.000409	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CA2—kidney cancer	0.000103	0.00112	CbGpPWpGaD
Dolutegravir—Diarrhoea—Doxorubicin—kidney cancer	0.000101	0.000396	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ALAD—kidney cancer	0.000101	0.00109	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ST3GAL2—kidney cancer	9.82e-05	0.00106	CbGpPWpGaD
Dolutegravir—Dizziness—Doxorubicin—kidney cancer	9.8e-05	0.000382	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ALDH1A1—kidney cancer	9.6e-05	0.00104	CbGpPWpGaD
Dolutegravir—Vomiting—Doxorubicin—kidney cancer	9.42e-05	0.000368	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—kidney cancer	9.34e-05	0.000365	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—kidney cancer	9.34e-05	0.000364	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—kidney cancer	9.28e-05	0.000362	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—SLC5A3—kidney cancer	9.21e-05	0.000997	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PGK1—kidney cancer	9.21e-05	0.000997	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—LDHB—kidney cancer	9.03e-05	0.000978	CbGpPWpGaD
Dolutegravir—Nausea—Doxorubicin—kidney cancer	8.8e-05	0.000343	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CA9—kidney cancer	7.83e-05	0.000848	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CRABP1—kidney cancer	6.66e-05	0.000721	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ITPR2—kidney cancer	6.19e-05	0.00067	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTT1—kidney cancer	5.64e-05	0.000611	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ACHE—kidney cancer	5.64e-05	0.000611	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SCARB1—kidney cancer	5.34e-05	0.000579	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS1—kidney cancer	5.29e-05	0.000573	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PSMD7—kidney cancer	5.19e-05	0.000562	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—BCHE—kidney cancer	4.92e-05	0.000532	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC5A5—kidney cancer	4.86e-05	0.000526	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC2A1—kidney cancer	4.69e-05	0.000508	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTP1—kidney cancer	3.91e-05	0.000424	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCB1—kidney cancer	3.7e-05	0.000401	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—kidney cancer	3.59e-05	0.000389	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1A1—kidney cancer	3.41e-05	0.000369	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—POMC—kidney cancer	2.54e-05	0.000275	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—kidney cancer	2.03e-05	0.000219	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—kidney cancer	1.77e-05	0.000191	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—kidney cancer	1.25e-05	0.000135	CbGpPWpGaD
